| Literature DB >> 29097838 |
Ayano Hirako1, Yuki Takeoka1, Satoshi Furukawa2, Akihiko Sugiyama1.
Abstract
For the purpose of clarifying the histopathological effects of methotrexate (MTX) on medaka testes, wild-type and homogenic p53-deficient male medaka at 4 to 6 months post-hatching were exposed to 0.25 mg/ml of MTX for 96 h with histopathological examination of testes at 24, 48, 72 and 96 h. At 72 and 96 h after the start of MTX exposure, numerous apoptotic cells were observed in the spermatogonia and spermatocytes, and the pyknotic cell rate and the TUNEL-positive and cleaved caspase-3-positive rates in the spermatogonia and spermatocytes of MTX-treated wild type medaka were higher compared with those in the control wild-type medaka. Starting at 48 h, the phospho-histone H3-positive rate in the spermatogonia and spermatocytes of was significantly lower in MTX-treated wild-type medaka than in control wild-type medaka. In homogenic p53-deficient medaka, apoptosis was not induced in the spermatogonia and spermatocytes by exposure to MTX. Starting at 48 h, the phospho-histone H3-positive rate in spermatogonia and spermatocytes of MTX-treated homogenic p53-deficient medaka was lower than in control homogenic p53-deficient medaka. Throughout the entire experimental period, there were no significant differences in phospho-histone H3-positive rates in the spermatogonia and spermatocytes between the MTX-treated homogenic p53-deficient medaka group and the MTX-treated wild-type medaka group. In the present study, spermatogonia and spermatocytes of medaka testes were sensitive to MTX at 0.25 mg/ml in the culture water, and MTX-induced apoptosis in the testes was dependent on p53 expression; however, inhibition of MTX-induced cell proliferation was independent of p53 expression.Entities:
Keywords: apoptosis; cell proliferation inhibition; p53; spermatocyte; spermatogonia
Year: 2017 PMID: 29097838 PMCID: PMC5660950 DOI: 10.1293/tox.2017-0029
Source DB: PubMed Journal: J Toxicol Pathol ISSN: 0914-9198 Impact factor: 1.628
Time Course Changes in Pyknotic Index, TUNEL-positive Rate, and Cleaved Caspase 3-positive Rate in Spermatogonia and Spermatocytes
Fig. 1.Pyknotic changes in spermatogonia and spermatocytes after 96 h MTX treatment. A. Control wild-type medaka group. B. MTX-treated wild-type medaka group. C. Control homogenic p53-deficient (p53 (−/−)) medaka group. D. MTX-treated homogenic p53-deficient (p53 (−/−)) medaka group. Arrows indicate pyknosis. Bar = 30 μm.
Fig. 2.TUNEL-positive cells in spermatogonia and spermatocytes after 96 h MTX treatment. A. Control wild-type medaka group. B. MTX-treated wild-type medaka group. C. Control homogenic p53-deficient (p53 (−/−)) medaka group. D. MTX-treated homogenic p53-deficient (p53 (−/−)) medaka group. Bar = 30 μm.
Fig. 3.Cleaved caspase-3-positive cells in spermatogonia and spermatocytes after 96 h MTX treatment. A. Control wild-type medaka group. B. MTX-treated wild-type medaka group. C. Control homogenic p53-deficient (p53 (−/−)) medaka group. D. MTX-treated homogenic p53-deficient (p53 (−/−)) medaka group. Bar = 30 μm.
Fig. 4.Phospho-histone H3-positive cells in spermatogonia and spermatocytes after 96 h MTX treatment. A. Control wild-type medaka group. B. MTX-treated wild-type medaka group. C. Control homogenic p53-deficient (p53 (−/−)) medaka group. D. MTX-treated homogenic p53-deficient (p53 (−/−)) medaka group. Bar = 30 μm.
Time Course Changes in Phospho-histone H3-positive Rate (%) in Spermatogonia and Spermatocytes